Treatment extension of pegylated interferon alpha and ribavirin does not improve SVR in patients with genotypes 2/3 without rapid virological response (OPTEX Trial): A prospective, randomized, two-arm, multicentre phase IV clinical trial

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Heidrich, Benjamin ^a,b,c   Cordes, Hans Jörg ^d   Klinker, Hartwig ^e   Möller, Bernd ^f   Naumann, Uwe ^g   Rössle, Martin ^h   Kraus, Michael R ⁱ   Böker, Klaus H ^d   Roggel, Christoph ^d   Schuchmann, Marcus ^j   Stoehr, Albrecht ^k   Trein, Andreas ^d   Hardtke, Svenja ^a,b,c   Gonnermann, Andrea ^a   Koch, Armin ^a   Wedemeyer, Heiner ^a,b,c   Manns, Michael P ^a,b,c   Cornberg, Markus ^a,b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN RESEARCH FOUNDATION   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d University of Würzburg ^*  (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f Leberzentrum   (Germany)

^g Center for Space Medicine   (Germany)

^h Praxiszentrum Gastroenterologie und Endokrinologie   (Germany)

ⁱ District Hospital Altötting Burghausen   (Germany)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON;

ADULT; ANEMIA; ARTICLE; CHOLECYSTITIS; CONTROLLED STUDY; DEHYDRATION; DISEASE REGISTRY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; FEVER; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PERICARDIAL EFFUSION; PHASE 4 CLINICAL TRIAL; PLEURA EFFUSION; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RAPID VIROLOGICAL RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRE; RECURRENT DISEASE; STATISTICAL MODEL; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84936851044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128069     Document Type: Article

References (23)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; doi: 10.1016/j.jhep.2014.07.027
2. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014; 21 Suppl 1: 34-59. doi: 10.1111/jvh.12248 PMID: 24713005
3. Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut. 2012; 61: 1647-1652. doi: 10.1136/gutjnl-2012-302910 PMID: 22936671
4. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012; 56 Suppl 1: S88-100. doi: 10.1016/S0168-8278(12)60010-5 PMID: 22300469
5. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 1867-1877. doi: 10.1056/NEJMoa1214854 PMID: 23607593
6. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-1887. doi: 10.1056/NEJMoa1214853 PMID: 23607594
7. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370: 1993-2001. doi: 10.1056/NEJMoa1316145 PMID: 24795201
8. Aktuelle Empfehlung der DGVS zur Therapie der chronischen Hepatitis C-DGVS [Internet]. [cited 11 Jun 2014]. Available: http://www.dgvs.de/leitlinien/aktuelle-empfehlungen/aktuelle-empfehlung-derdgvs-zur-therapie-der-chronischen-hepatitis-c/
9. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60: 392-420. doi: 10.1016/j.jhep.2013.11.003 PMID: 24331294
10. Sarin SK, Kumar CKN. Treatment of patients with genotype 3 chronic hepatitis C-current and future therapies. Liver Int Off J Int Assoc Study Liver. 2012; 32 Suppl 1: 141-145. doi: 10.1111/j.1478-3231.2011.02715.x PMID: 22212585
11. Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther. 2014; 39: 686-698. doi: 10.1111/apt.12646 PMID: 24612116
12. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 2609-2617. doi: 10.1056/NEJMoa042608 PMID: 15972867
13. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatol Baltim Md. 2008; 47: 35-42. doi: 10.1002/hep.21975
14. Yu M-L, Dai C-Y, Huang J-F, Hou N-J, Lee L-P, Hsieh M-Y, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007; 56:553-559. doi: 10.1136/gut.2006.102558 PMID: 16956917
15. Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, et al. Treatment of Nai¨ve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. PloS One. 2014; 9: e108751. doi: 10.1371/journal.pone.0108751 PMID: 25302676
16. Yamaguchi Y, Tamori A, Tanaka Y, Iwai S, Kobayashi S, Fujii H, et al. Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatol Res Off J Jpn Soc Hepatol. 2012; 42: 549-557. doi: 10.1111/j.1872-034X.2011.00956.x
17. Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129: 522-527. doi: 10.1016/j.gastro.2005.05.008 PMID: 16083709
18. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40: 993-999. doi: 10.1016/j.jhep.2004.02.007 PMID: 15158341
19. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008; 28: 397-404. doi: 10.1111/j.1365-2036.2008.03763.x PMID: 18549461
20. Ellert U, Kurth B- M. [Methodological views on the SF-36 summary scores based on the adult German population]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004; 47: 1027-1032. doi: 10.1007/s00103-004-0933-1 PMID: 15549195
21. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401. doi: 10.1038/nature08309 PMID: 19684573
22. Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol. 2014; 61: 235-241. doi: 10.1016/j.jhep.2014.03.039 PMID: 24768758
23. Huang C-F, Yang J-F, Huang J-F, Dai C-Y, Chiu C-F, Hou N-J, et al. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol. 2010; 25: 758-765. doi: 10.1111/j.1440-1746.2009.06148.x PMID: 20492331